Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLWAVE-011: Nemtabrutinib vs Ibrutinib/Acalabrutinib in Untreated CLL/SLL
NCT06136559Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Primary completion
- Sep 2032
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of nemtabrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Merck & Co.. Started Dec 2023; status: recruiting.
02
Drugs
nemtabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06136559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06136559.